Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269458 | 0.84 | CYP2D6 (0.61) | KMT2AMEN1SIGMAR1CHRM2CYP2D6 | |
| SCHEMBL8970760 | 0.83 | KCNA3 (0.63) | OPRM1LMNAOPRD1OPRK1 | |
| SCHEMBL8491426 | 0.81 | SLC6A3 (0.54) | SLC6A3KMT2AMEN1KCNH2SIGMAR1 | |
| SCHEMBL7289267 | 0.80 | SIGMAR1 (0.53) | SLC6A3KMT2AMEN1KCNH2SIGMAR1 | |
| SCHEMBL18203104 | 0.80 | SLC6A3 (0.53) | SLC6A3KMT2AMEN1KCNH2SIGMAR1 | |
| SCHEMBL3554958 | 0.80 | KCNA3 (0.60) | SLC6A3KMT2AMEN1KCNH2SIGMAR1 | |
| SCHEMBL8970769 | 0.79 | SLC6A3 (0.56) | SLC6A3KMT2AMEN1SIGMAR1OPRM1 | |
| Hydrochloric Acid SCHEMBL18191772 | 0.79 | SLC6A3 (0.51) | SLC6A3KMT2AMEN1KCNH2SIGMAR1 | |
| SCHEMBL4293243 | 0.78 | DRD2 (0.55) | CHRM2CYP2D6TSHR | |
| SCHEMBL8970828 | 0.78 | SIGMAR1 (0.56) | SLC6A3KMT2AKCNH2SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | SLC6A3 480/4885KMT2A 3265/4885MEN1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.